

# Matteo Fornai

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2783716/matteo-fornai-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

131  
papers

3,488  
citations

35  
h-index

51  
g-index

141  
ext. papers

4,166  
ext. citations

6  
avg, IF

5.22  
L-index

#	Paper	IF	Citations
131	Enteric Lysine impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson's disease before brain pathology.. <i>Npj Parkinson Disease</i> , <b>2022</b> , 8, 9	9.7	3
130	Anti-inflammatory Effects of Novel P2X4 Receptor Antagonists, NC-2600 and NP-1815-PX, in a Murine Model of Colitis.. <i>Inflammation</i> , <b>2022</b> , 1	5.1	1
129	Donepezil improves vascular function in a mouse model of Alzheimer's disease. <i>Pharmacology Research and Perspectives</i> , <b>2021</b> , 9, e00871	3.1	1
128	Preclinical Development of FA5, a Novel AMP-Activated Protein Kinase (AMPK) Activator as an Innovative Drug for the Management of Bowel Inflammation. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
127	NLRP3 at the crossroads between immune/inflammatory responses and enteric neuroplastic remodelling in a mouse model of diet-induced obesity. <i>British Journal of Pharmacology</i> , <b>2021</b> , 178, 3924-3942	8.6	5
126	Adenosine Signaling in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , <b>2021</b> , 1270, 145-167	3.6	4
125	The role of serotonin and its pathways in gastrointestinal disorders <b>2021</b> , 67-94		1
124	NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implications. <i>Medicinal Research Reviews</i> , <b>2021</b> , 41, 1890-1926	14.4	12
123	Palmitoylethanolamide Counteracts Enteric Inflammation and Bowel Motor Dysfunctions in a Mouse Model of Alzheimer's Disease. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 748021	5.6	2
122	Prodromal Intestinal Events in Alzheimer's Disease (AD): Colonic Dysmotility and Inflammation Are Associated with Enteric AD-Related Protein Deposition. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	10
121	NKG2A and COVID-19: another brick in the wall. <i>Cellular and Molecular Immunology</i> , <b>2020</b> , 17, 672-674	15.4	44
120	Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications?. <i>Progress in Neurobiology</i> , <b>2020</b> , 191, 101806	10.9	38
119	Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 284-291	6.1	19
118	Approaches for designing and discovering purinergic drugs for gastrointestinal diseases. <i>Expert Opinion on Drug Discovery</i> , <b>2020</b> , 15, 687-703	6.2	5
117	Role of proteinase-activated receptors 1 and 2 in nonsteroidal anti-inflammatory drug enteropathy. <i>Pharmacological Reports</i> , <b>2020</b> , 72, 1347-1357	3.9	3
116	The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A Receptor Agonist, in a Rat Model of Colitis. <i>Cells</i> , <b>2020</b> , 9,	7.9	6
115	Ectopic Lymphoid Organs and Immune-Mediated Diseases: Molecular Basis for Pharmacological Approaches. <i>Trends in Molecular Medicine</i> , <b>2020</b> , 26, 1021-1033	11.5	7

114	Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients. <i>British Journal of Clinical Pharmacology</i> , <b>2020</b> , 86, 1296-1305	3.8	16
113	Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration. <i>Neurobiology of Disease</i> , <b>2020</b> , 139, 104821	7.5	11
112	Colonic dysmotility associated with high-fat diet-induced obesity: Role of enteric glia. <i>FASEB Journal</i> , <b>2020</b> , 34, 5512-5524	0.9	20
111	Differential Impact of Weight Loss and Glycemic Control on Inflammasome Signaling. <i>Obesity</i> , <b>2020</b> , 28, 609-615	8	6
110	Glial A Adenosine Receptors Modulate Abnormal Tachykininergic Responses and Prevent Enteric Inflammation Associated with High Fat Diet-Induced Obesity. <i>Cells</i> , <b>2020</b> , 9,	7.9	12
109	Intestinal epithelial barrier and neuromuscular compartment in health and disease. <i>World Journal of Gastroenterology</i> , <b>2020</b> , 26, 1564-1579	5.6	14
108	P454 Serum oncostatin M predicts mucosal healing in Crohn's disease patients treated with infliximab. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, S406-S406	1.5	
107	Enteric Glia at the Crossroads between Intestinal Immune System and Epithelial Barrier: Implications for Parkinson Disease. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	7
106	Deepening the Mechanisms of Visceral Pain Persistence: An Evaluation of the Gut-Spinal Cord Relationship. <i>Cells</i> , <b>2020</b> , 9,	7.9	11
105	Inflammatory Bowel Diseases: It's Time for the Adenosine System. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 1310	8.4	4
104	The Adenosine System at the Crossroads of Intestinal Inflammation and Neoplasia. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	5
103	Protective effects of the combination Bifidobacterium longum plus lactoferrin against NSAID-induced enteropathy. <i>Nutrition</i> , <b>2020</b> , 70, 110583	4.8	12
102	Managing Obesity and Related Comorbidities: A Potential Pharmacological Target in the Adenosine System?. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 621955	5.6	2
101	P709 Early measurement of serum cytokines as predictor of clinical and endoscopic outcome to vedolizumab in patients with ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, S475-S475	1.5	
100	Phytochemicals as Novel Therapeutic Strategies for NLRP3 Inflammasome-Related Neurological, Metabolic, and Inflammatory Diseases. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	43
99	P2X4 receptors, immunity, and sepsis. <i>Current Opinion in Pharmacology</i> , <b>2019</b> , 47, 65-74	5.1	14
98	Constipation, deficit in colon contractions and alpha-synuclein inclusions within the colon precede motor abnormalities and neurodegeneration in the central nervous system in a mouse model of alpha-synucleinopathy. <i>Translational Neurodegeneration</i> , <b>2019</b> , 8, 5	10.3	28
97	Interplay between colonic inflammation and tachykininergic pathways in the onset of colonic dysmotility in a mouse model of diet-induced obesity. <i>International Journal of Obesity</i> , <b>2019</b> , 43, 331-343	5.5	18

96	High Levels of $\beta$ -Amyloid, Tau, and Phospho-Tau in Red Blood Cells as Biomarkers of Neuropathology in Senescence-Accelerated Mouse. <i>Oxidative Medicine and Cellular Longevity</i> , <b>2019</b> , 2019, 5030475	6.7	14
95	Evaluation of cytokine levels as putative biomarkers to predict the pharmacological response to biologic therapy in inflammatory bowel diseases. <i>Minerva Gastroenterologica E Dietologica</i> , <b>2019</b> , 65, 298-308	1.6	5
94	Risankizumab for the treatment of moderate to severe psoriasis. <i>Expert Opinion on Biological Therapy</i> , <b>2019</b> , 19, 1-8	5.4	4
93	Adenosine signaling and the immune system: When a lot could be too much. <i>Immunology Letters</i> , <b>2019</b> , 205, 9-15	4.1	80
92	Neuronal regulation of intestinal immune functions in health and disease. <i>Neurogastroenterology and Motility</i> , <b>2018</b> , 30, e13406	4	10
91	Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 212	5.6	13
90	Adenosine Regulation of the Immune System <b>2018</b> , 499-514		4
89	The flavonoid compound apigenin prevents colonic inflammation and motor dysfunctions associated with high fat diet-induced obesity. <i>PLoS ONE</i> , <b>2018</b> , 13, e0195502	3.7	33
88	Dietary flavonoids as a potential intervention to improve redox balance in obesity and related co-morbidities: a review. <i>Nutrition Research Reviews</i> , <b>2018</b> , 31, 239-247	7	26
87	The flavonoid compound luteolin prevents endothelial dysfunction in a mouse model of high fat diet-induced obesity. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , <b>2018</b> , WCP2018, PO4-2-47	0	
86	FA-5, a novel AMP-activated protein kinase (AMPK) activator, as a new pharmacological tool for the management of bowel inflammation. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , <b>2018</b> , WCP2018, PO3-5-2	0	
85	Rifaximin prevents diclofenac-induced enteropathy in rats through antibacterial and anti-inflammatory activities. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , <b>2018</b> , WCP2018, PO3-5-28	0	
84	A comparative study on the efficacy of NLRP3 inflammasome signaling inhibitors in a pre-clinical model of bowel inflammation. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , <b>2018</b> , WCP2018, PO2-6-29	0	
83	Anti-inflammatory effect of a novel locally acting A receptor agonist in a rat model of oxazolone-induced colitis. <i>Purinergic Signalling</i> , <b>2018</b> , 14, 27-36	3.8	11
82	Pathophysiology of NSAID-Associated Intestinal Lesions in the Rat: Luminal Bacteria and Mucosal Inflammation as Targets for Prevention. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 1340	5.6	24
81	A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 1405	5.6	22
80	Luteolin Prevents Cardiometabolic Alterations and Vascular Dysfunction in Mice With HFD-Induced Obesity. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 1094	5.6	33
79	Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases?. <i>Acta Neuropathologica</i> , <b>2018</b> , 136, 345-361	14.3	103

78	Development of an Acrylate Derivative Targeting the NLRP3 Inflammasome for the Treatment of Inflammatory Bowel Disease. <i>Journal of Medicinal Chemistry</i> , <b>2017</b> , 60, 3656-3671	8.3	95
77	Intestinal Fungal Dysbiosis Is Associated With Visceral Hypersensitivity in Patients With Irritable Bowel Syndrome and Rats. <i>Gastroenterology</i> , <b>2017</b> , 153, 1026-1039	13.3	108
76	Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. <i>Neuropharmacology</i> , <b>2017</b> , 123, 22-33	5.5	13
75	Colonic motor dysfunctions in a mouse model of high-fat diet-induced obesity: an involvement of A adenosine receptors. <i>Purinergic Signalling</i> , <b>2017</b> , 13, 497-510	3.8	24
74	Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies. <i>Drug Discovery Today</i> , <b>2017</b> , 22, 1686-1696	8.8	50
73	Canonical and Non-Canonical Activation of NLRP3 Inflammasome at the Crossroad between Immune Tolerance and Intestinal Inflammation. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 36	8.4	93
72	Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. <i>Journal of Neuroinflammation</i> , <b>2016</b> , 13, 146	10.1	50
71	Tu1889 Targeting of NLRP3 Inflammasome With a Novel Selective Inhibitor as a Suitable Strategy for the Pharmacological Treatment of Bowel Inflammation. <i>Gastroenterology</i> , <b>2016</b> , 150, S968-S969	13.3	3
70	Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects. <i>Drug Safety</i> , <b>2016</b> , 39, 903-24	5.1	18
69	Enteric Dysfunctions in Experimental Parkinson's Disease: Alterations of Excitatory Cholinergic Neurotransmission Regulating Colonic Motility in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2016</b> , 356, 434-44	4.7	36
68	Small bowel protection against NSAID-injury in rats: Effect of rifaximin, a poorly absorbed, GI targeted, antibiotic. <i>Pharmacological Research</i> , <b>2016</b> , 104, 186-96	10.2	22
67	The AMPK enzyme-complex: from the regulation of cellular energy homeostasis to a possible new molecular target in the management of chronic inflammatory disorders. <i>Expert Opinion on Therapeutic Targets</i> , <b>2016</b> , 20, 179-91	6.4	26
66	Intestinal dysfunction in Parkinson's disease: Lessons learned from translational studies and experimental models. <i>Neurogastroenterology and Motility</i> , <b>2016</b> , 28, 1781-1791	4	31
65	Genetics and pharmacogenetics of aminergic transmitter pathways in functional gastrointestinal disorders. <i>Pharmacogenomics</i> , <b>2015</b> , 16, 523-39	2.6	9
64	Comment on "High expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma". <i>Tumor Biology</i> , <b>2015</b> , 36, 7397-8	2.9	1
63	Gastric motor dysfunctions in Parkinson's disease: Current pre-clinical evidence. <i>Parkinsonism and Related Disorders</i> , <b>2015</b> , 21, 1407-14	3.6	43
62	Safety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis. <i>Drug Safety</i> , <b>2015</b> , 38, 869-88	5.1	12
61	Allopurinol adherence among patients with gout: an Italian general practice database study. <i>International Journal of Clinical Practice</i> , <b>2015</b> , 69, 757-65	2.9	26

60	Adverse reactions to oncologic drugs: spontaneous reporting and signal detection. <i>Expert Review of Clinical Pharmacology</i> , <b>2015</b> , 8, 61-75	3.8	19
59	An integrated assessment of histopathological changes of the enteric neuromuscular compartment in experimental colitis. <i>Journal of Cellular and Molecular Medicine</i> , <b>2015</b> , 19, 485-500	5.6	20
58	Adenosine and inflammation: what's new on the horizon?. <i>Drug Discovery Today</i> , <b>2014</b> , 19, 1051-68	8.8	107
57	Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management. <i>CNS Drugs</i> , <b>2014</b> , 28, 249-72	6.7	41
56	NSAID-induced enteropathy: are the currently available selective COX-2 inhibitors all the same?. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2014</b> , 348, 86-95	4.7	36
55	Involvement of the P2X7 purinergic receptor in colonic motor dysfunction associated with bowel inflammation in rats. <i>PLoS ONE</i> , <b>2014</b> , 9, e116253	3.7	34
54	Role of the A(2B) receptor-adenosine deaminase complex in colonic dysmotility associated with bowel inflammation in rats. <i>British Journal of Pharmacology</i> , <b>2014</b> , 171, 1314-29	8.6	24
53	Role of cyclooxygenase isoforms in the altered excitatory motor pathways of human colon with diverticular disease. <i>British Journal of Pharmacology</i> , <b>2014</b> , 171, 3728-40	8.6	9
52	Quality of Adverse Drug Reaction (QADRA) reports: an algorithm to appraise the efficiency of spontaneous reporting systems in pharmacovigilance. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , <b>2013</b> , 21, 365-372	1.4	4
51	The role of purinergic pathways in the pathophysiology of gut diseases: pharmacological modulation and potential therapeutic applications. <i>Pharmacology &amp; Therapeutics</i> , <b>2013</b> , 139, 157-88	13.9	45
50	Response to Endothelial nitric oxide synthase, cyclooxygenase-2, and essential hypertension: is there an interaction?. <i>Hypertension</i> , <b>2013</b> , 62, e16	8.5	1
49	Rosuvastatin prevents angiotensin II-induced vascular changes by inhibition of NAD(P)H oxidase and COX-1. <i>British Journal of Pharmacology</i> , <b>2013</b> , 169, 554-66	8.6	14
48	Endothelial dysfunction in small arteries of essential hypertensive patients: role of cyclooxygenase-2 in oxidative stress generation. <i>Hypertension</i> , <b>2013</b> , 62, 337-44	8.5	84
47	Influence of the serotonin transporter 5HTTLPR polymorphism on symptom severity in irritable bowel syndrome. <i>PLoS ONE</i> , <b>2013</b> , 8, e54831	3.7	34
46	Nonsteroidal anti-inflammatory drug-activated gene-1 plays a role in the impairing effects of cyclooxygenase inhibitors on gastric ulcer healing. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2012</b> , 342, 140-9	4.7	13
45	Telogen effluvium following bivalent human papillomavirus vaccine administration: a report of two cases. <i>Dermatology</i> , <b>2012</b> , 224, 212-4	4.4	11
44	Resistance artery mechanics and composition in angiotensin II-infused mice: effects of cyclooxygenase-1 inhibition. <i>European Heart Journal</i> , <b>2012</b> , 33, 2225-34	9.5	26
43	Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders. <i>Current Drug Targets</i> , <b>2012</b> , 13, 842-62	3	96

42	Effects of esomeprazole on healing of nonsteroidal anti-inflammatory drug (NSAID)-induced gastric ulcers in the presence of a continued NSAID treatment: Characterization of molecular mechanisms. <i>Pharmacological Research</i> , <b>2011</b> , 63, 59-67	10.2	29
41	Drug-induced taste and smell alterations: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting. <i>Drug Safety</i> , <b>2011</b> , 34, 849-59	5.1	36
40	Safety of MF-59 adjuvanted vaccine for pandemic influenza: results of the vaccination campaign in an Italian health district. <i>Vaccine</i> , <b>2011</b> , 29, 3443-8	4.1	11
39	Pathophysiology of Gastric Ulcer Development and Healing: Molecular Mechanisms and Novel Therapeutic Options <b>2011</b> ,		11
38	Differential recruitment of high affinity A1 and A2A adenosine receptors in the control of colonic neuromuscular function in experimental colitis. <i>European Journal of Pharmacology</i> , <b>2011</b> , 650, 639-49	5.3	34
37	Derivatives of benzimidazol-2-ylquinoline and benzimidazol-2-ylisoquinoline as selective A1 adenosine receptor antagonists with stimulant activity on human colon motility. <i>ChemMedChem</i> , <b>2011</b> , 6, 1909-18	3.7	15
36	Control of enteric neuromuscular functions by purinergic A(3) receptors in normal rat distal colon and experimental bowel inflammation. <i>British Journal of Pharmacology</i> , <b>2010</b> , 161, 856-71	8.6	25
35	The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2010</b> , 335, 434-42	4.7	41
34	Inclusion of rituximab in treatment protocols for non-Hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathy. <i>Oncologist</i> , <b>2010</b> , 15, 1214-9	5.7	43
33	Use of selective serotonin reuptake inhibitors during pregnancy and risk of major and cardiovascular malformations: an update. <i>Postgraduate Medicine</i> , <b>2010</b> , 122, 49-65	3.7	29
32	Transient acute liver failure complicating transurethral resection syndrome. <i>Scandinavian Journal of Urology and Nephrology</i> , <b>2010</b> , 44, 269-72		3
31	Emerging role of cyclooxygenase isoforms in the control of gastrointestinal neuromuscular functions. <i>Pharmacology &amp; Therapeutics</i> , <b>2010</b> , 125, 62-78	13.9	24
30	Atorvastatin prevents endothelial dysfunction in mesenteric arteries from spontaneously hypertensive rats: role of cyclooxygenase 2-derived contracting prostanoids. <i>Hypertension</i> , <b>2009</b> , 53, 1008-16	8.5	56
29	Inducible nitric oxide synthase is involved in endothelial dysfunction of mesenteric small arteries from hypothyroid rats. <i>Endocrinology</i> , <b>2009</b> , 150, 1033-42	4.8	32
28	Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review. <i>Clinical Therapeutics</i> , <b>2009</b> , 31 Pt 1, 1426-53	3.5	78
27	Effects of pantoprazole on ulcer healing delay associated with NSAID treatment. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>2009</b> , 379, 305-13	3.4	4
26	A1 and A2a receptors mediate inhibitory effects of adenosine on the motor activity of human colon. <i>Neurogastroenterology and Motility</i> , <b>2009</b> , 21, 451-66	4	23
25	Characterization of mechanisms underlying the effects of esomeprazole on the impairment of gastric ulcer healing with addition of NSAID treatment. <i>Digestive and Liver Disease</i> , <b>2009</b> , 41, 395-405	3.3	20

24	Role of coxibs in the strategies for gastrointestinal protection in patients requiring chronic non-steroidal anti-inflammatory therapy. <i>Pharmacological Research</i> , <b>2009</b> , 59, 90-100	10.2	32
23	Exploiting the pyrazolo[3,4-d]pyrimidin-4-one ring system as a useful template to obtain potent adenosine deaminase inhibitors. <i>Journal of Medicinal Chemistry</i> , <b>2009</b> , 52, 1681-92	8.3	38
22	Regulation of enteric functions by adenosine: pathophysiological and pharmacological implications <b>2008</b> , 120, 233-53		88
21	Clinical efficacy of esomeprazole in the prevention and healing of gastrointestinal toxicity associated with NSAIDs in elderly patients. <i>Drugs and Aging</i> , <b>2008</b> , 25, 197-208	4.7	21
20	Pharmacological modulation of adenosine system: novel options for treatment of inflammatory bowel diseases. <i>Inflammatory Bowel Diseases</i> , <b>2008</b> , 14, 566-74	4.5	51
19	Effects of a bicarbonate-alkaline mineral water on digestive motility in experimental models of functional and inflammatory gastrointestinal disorders. <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , <b>2008</b> , 30, 261-9		8
18	Tolerability profiles of leukotriene receptor antagonists and long-acting beta2-adrenoceptor agonists in combination with inhaled corticosteroids for treatment of asthma: a review. <i>Journal of Asthma</i> , <b>2007</b> , 44, 411-22	1.9	3
17	Cholecystokinin CCK2 receptors mediate the peptide's inhibitory actions on the contractile activity of human distal colon via the nitric oxide pathway. <i>British Journal of Pharmacology</i> , <b>2007</b> , 151, 1246-53	8.6	12
16	CCK2 receptors mediate inhibitory effects of cholecystokinin on the motor activity of guinea-pig distal colon. <i>European Journal of Pharmacology</i> , <b>2007</b> , 557, 212-20	5.3	7
15	Cyclooxygenase-1 is involved in endothelial dysfunction of mesenteric small arteries from angiotensin II-infused mice. <i>Hypertension</i> , <b>2007</b> , 49, 679-86	8.5	63
14	Inhibition of adenosine deaminase attenuates inflammation in experimental colitis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2007</b> , 322, 435-42	4.7	86
13	Differential role of cyclooxygenase 1 and 2 isoforms in the modulation of colonic neuromuscular function in experimental inflammation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2006</b> , 317, 938-45	4.7	29
12	Cyclooxygenase-2 induction after oral surgery does not entirely account for analgesia after selective blockade of cyclooxygenase 2 in the preoperative period. <i>Anesthesiology</i> , <b>2006</b> , 104, 152-7	4.3	6
11	Constitutive expression of cyclooxygenase-2 in the neuromuscular compartment of normal human colon. <i>Neurogastroenterology and Motility</i> , <b>2006</b> , 18, 654-62	4	22
10	A2a receptors mediate inhibitory effects of adenosine on colonic motility in the presence of experimental colitis. <i>Inflammatory Bowel Diseases</i> , <b>2006</b> , 12, 117-22	4.5	34
9	Cyclooxygenase-2 inhibition improves vascular endothelial dysfunction in a rat model of endotoxic shock: role of inducible nitric-oxide synthase and oxidative stress. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2005</b> , 312, 945-53	4.7	79
8	Clinical evaluation of piroxicam-FDDF and azithromycin in the prevention of complications associated with impacted lower third molar extraction. <i>Pharmacological Research</i> , <b>2005</b> , 52, 485-90	10.2	23
7	Mechanisms of protection by pantoprazole against NSAID-induced gastric mucosal damage. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>2005</b> , 372, 79-87	3.4	35



6	Role of cyclooxygenases 1 and 2 in the modulation of neuromuscular functions in the distal colon of humans and mice. <i>Gut</i> , <b>2005</b> , 54, 608-16	19.2	41
5	Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage. <i>World Journal of Gastroenterology</i> , <b>2005</b> , 11, 4052-60	5.6	55
4	Mechanisms of gastroprotection by lansoprazole pretreatment against experimentally induced injury in rats: role of mucosal oxidative damage and sulfhydryl compounds. <i>Toxicology and Applied Pharmacology</i> , <b>2004</b> , 195, 62-72	4.6	49
3	Altered prejunctional modulation of intestinal cholinergic and noradrenergic pathways by alpha2-adrenoceptors in the presence of experimental colitis. <i>British Journal of Pharmacology</i> , <b>2003</b> , 139, 309-20	8.6	66
2	Improved tonsillar disposition of azithromycin following a 3-day oral treatment with 20 mg kg <sup>-1</sup> in paediatric patients. <i>Pharmacological Research</i> , <b>2002</b> , 46, 95-100	10.2	1
1	Efficacy and Tolerability of Meloxicam, a COX-2 Preferential Nonsteroidal Anti-Inflammatory Drug. <i>Clinical Drug Investigation</i> , <b>2002</b> , 22, 799-818	3.2	47